Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing levels of lung function impairment
A. Wells (London, United Kingdom), W. Wuyts (Leuven, Belgium), S. Gläser (Berlin, Germany), A. Guillen-Del-Castillo (Barcelona, Spain), H. Nunes (Bobigny, France), M. Okamoto (Kurume, Japan), R. Simonovska (Sulzbach (Taunus), Germany), M. Alves (Ingelheim am Rhein, Germany), K. Highland (Cleveland, OH, United States)
Source: International Congress 2022 – Hot topics in connective tissue disease-associated interstitial lung disease
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Wells (London, United Kingdom), W. Wuyts (Leuven, Belgium), S. Gläser (Berlin, Germany), A. Guillen-Del-Castillo (Barcelona, Spain), H. Nunes (Bobigny, France), M. Okamoto (Kurume, Japan), R. Simonovska (Sulzbach (Taunus), Germany), M. Alves (Ingelheim am Rhein, Germany), K. Highland (Cleveland, OH, United States). Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing levels of lung function impairment. 1454
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|